Literature DB >> 21984966

Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde.

Noriko Takuwa, Wa Du, Erika Kaneko, Yasuo Okamoto, Kazuaki Yoshioka, Yoh Takuwa.   

Abstract

Sphingosine-1-phosphate (S1P) is a plasma lipid mediator with multiple roles in mammalian development, physiology and pathophysiology. It is constitutively produced mostly by erythrocytes by the action of sphingosine kinase 1 (SphK1), resulting in high (∼0.5 micromolar) steady-state plasma S1P content and steep S1P concentration gradient imposed between plasma/lymph/tissue interstitial fluid. S1P is also locally produced by activated platelets and tumor cells, in the latter case SphK1 is a downstream target of activated Ras mutant and hypoxia, and is frequently upregulated especially in advanced stages of tumors. Most if not all of the S1P actions in vertebrates are mediated through evolutionarily conserved G protein-coupled S1P receptor family. Ubiquitously expressed mammalian subtypes S1PR1, S1PR2 and S1PR3 mediate pleiotropic actions of S1P in diverse cell types, through coupling to distinctive repertoire of heterotrimeric G proteins. S1PR1 and S1PR3 mediate directed cell migration toward S1P through coupling to G(i) and activating Rac, a Rho family small G protein essential for cell migration. Indeed, S1PR1 expressed in lymphocytes directs their egress from lymph nodes into lymph and recirculation, serving as the target for downregulation by the immunosuppressant FTY720 (fingolimod). S1PR1 in endothelial cells plays an essential role in vascular maturation in embryonic stage, and mediates angiogenic and vascular protective roles of S1P which include eNOS activation and maintenance of barrier integrity. It is likely that S1PR1 and SphK1 expressed in host endothelial cells and tumor cells act in concert in a paracrine loop to contribute to tumor angiogenesis, tumor invasion and progression. In sharp contrast, S1PR2 mediates S1P inhibition of Rac at the site downstream of G(12/13)-mediated Rho activation, thus identified as the first G protein-coupled receptor that negatively regulates Rac and cell migration. S1PR2 could also mediate inhibition of Akt and cell proliferation/survival signaling via Rho-ROCK-PTEN pathway. S1PR2 expressed in tumor cells mediates inhibition of cell migration and invasion in vitro and metastasis in vivo. Moreover, S1PR2 expressed in host endothelial cells and tumor-infiltrating myeloid cells in concert mediates potent inhibition of tumor angiogenesis and tumor growth in vivo, with inhibition of VEGF expression and MMP9 activity. These recent findings provide further basis for S1P receptor subtype-specific, novel therapeutic tactics for individualized treatment of patients with cancer.

Entities:  

Keywords:  S1P receptors; Sphingosine-1-phosphate; metastasis; sphingosine kinase 1; tumor angiogenesis

Year:  2011        PMID: 21984966      PMCID: PMC3186046     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  172 in total

1.  FTY720 inhibits tumor growth and angiogenesis.

Authors:  G Schmid; M Guba; A Papyan; I Ischenko; M Brückel; C J Bruns; K-W Jauch; C Graeb
Journal:  Transplant Proc       Date:  2005 Jan-Feb       Impact factor: 1.066

Review 2.  p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment.

Authors:  Zhaohui Feng
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

3.  Intracellular calcium release mediated by sphingosine derivatives generated in cells.

Authors:  T K Ghosh; J Bian; D L Gill
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

4.  Molecular cloning and functional characterization of murine sphingosine kinase.

Authors:  T Kohama; A Olivera; L Edsall; M M Nagiec; R Dickson; S Spiegel
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

5.  Role for sphingosine kinase 1 in colon carcinogenesis.

Authors:  Toshihiko Kawamori; Tatsuya Kaneshiro; Masae Okumura; Samer Maalouf; Andre Uflacker; Jacek Bielawski; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2008-09-29       Impact factor: 5.191

6.  v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins.

Authors:  S Sobue; M Murakami; Y Banno; H Ito; A Kimura; S Gao; A Furuhata; A Takagi; T Kojima; M Suzuki; Y Nozawa; T Murate
Journal:  Oncogene       Date:  2008-06-23       Impact factor: 9.867

7.  Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity.

Authors:  Kayo Arikawa; Noriko Takuwa; Hironori Yamaguchi; Naotoshi Sugimoto; Joji Kitayama; Hirokazu Nagawa; Kazuhiko Takehara; Yoh Takuwa
Journal:  J Biol Chem       Date:  2003-06-16       Impact factor: 5.157

8.  Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate.

Authors:  Rajita Pappu; Susan R Schwab; Ivo Cornelissen; João P Pereira; Jean B Regard; Ying Xu; Eric Camerer; Yao-Wu Zheng; Yong Huang; Jason G Cyster; Shaun R Coughlin
Journal:  Science       Date:  2007-03-15       Impact factor: 47.728

Review 9.  Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function.

Authors:  Montserrat Serra; Julie D Saba
Journal:  Adv Enzyme Regul       Date:  2009-11-13

10.  Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog.

Authors:  Kiyoaki Yonesu; Yumi Kawase; Tatsuya Inoue; Nana Takagi; Jun Tsuchida; Yoh Takuwa; Seiichiro Kumakura; Futoshi Nara
Journal:  Biochem Pharmacol       Date:  2008-12-27       Impact factor: 5.858

View more
  26 in total

1.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Authors:  Ryan D Morin; Karen Mungall; Erin Pleasance; Andrew J Mungall; Rodrigo Goya; Ryan D Huff; David W Scott; Jiarui Ding; Andrew Roth; Readman Chiu; Richard D Corbett; Fong Chun Chan; Maria Mendez-Lago; Diane L Trinh; Madison Bolger-Munro; Greg Taylor; Alireza Hadj Khodabakhshi; Susana Ben-Neriah; Julia Pon; Barbara Meissner; Bruce Woolcock; Noushin Farnoud; Sanja Rogic; Emilia L Lim; Nathalie A Johnson; Sohrab Shah; Steven Jones; Christian Steidl; Robert Holt; Inanc Birol; Richard Moore; Joseph M Connors; Randy D Gascoyne; Marco A Marra
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

2.  Endothelial alterations in a canine model of immune thrombocytopenia.

Authors:  Dana N LeVine; Rachel E Cianciolo; Keith E Linder; Petra Bizikova; Adam J Birkenheuer; Marjory B Brooks; Abdelghaffar K Salous; Shila K Nordone; Dwight A Bellinger; Henry Marr; Sam L Jones; Thomas H Fischer; Yu Deng; Marshall Mazepa; Nigel S Key
Journal:  Platelets       Date:  2017-11-28       Impact factor: 3.862

3.  DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control.

Authors:  Helene Kretzmer; Stephan H Bernhart; Wei Wang; Andrea Haake; Marc A Weniger; Anke K Bergmann; Matthew J Betts; Enrique Carrillo-de-Santa-Pau; Gero Doose; Jana Gutwein; Julia Richter; Volker Hovestadt; Bingding Huang; Daniel Rico; Frank Jühling; Julia Kolarova; Qianhao Lu; Christian Otto; Rabea Wagener; Judith Arnolds; Birgit Burkhardt; Alexander Claviez; Hans G Drexler; Sonja Eberth; Roland Eils; Paul Flicek; Siegfried Haas; Michael Humme; Dennis Karsch; Hinrik H D Kerstens; Wolfram Klapper; Markus Kreuz; Chris Lawerenz; Dido Lenzek; Markus Loeffler; Cristina López; Roderick A F MacLeod; Joost H A Martens; Marta Kulis; José Ignacio Martín-Subero; Peter Möller; Inga Nage; Simone Picelli; Inga Vater; Marius Rohde; Philip Rosenstiel; Maciej Rosolowski; Robert B Russell; Markus Schilhabel; Matthias Schlesner; Peter F Stadler; Monika Szczepanowski; Lorenz Trümper; Hendrik G Stunnenberg; Ralf Küppers; Ole Ammerpohl; Peter Lichter; Reiner Siebert; Steve Hoffmann; Bernhard Radlwimmer
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

4.  Structure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors.

Authors:  Molly D Congdon; Yugesh Kharel; Anne M Brown; Stephanie N Lewis; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  ACS Med Chem Lett       Date:  2016-02-02       Impact factor: 4.345

5.  Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors.

Authors:  Molly D Congdon; Elizabeth S Childress; Neeraj N Patwardhan; James Gumkowski; Emily A Morris; Yugesh Kharel; Kevin R Lynch; Webster L Santos
Journal:  Bioorg Med Chem Lett       Date:  2015-03-23       Impact factor: 2.823

Review 6.  Chemo- and mechanosensing by dendritic cells facilitate antigen surveillance in the spleen.

Authors:  Dan Liu; Lihui Duan; Jason G Cyster
Journal:  Immunol Rev       Date:  2022-03       Impact factor: 12.988

7.  Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells.

Authors:  Shujun Xiao; Jian Yang
Journal:  Invest New Drugs       Date:  2018-06-02       Impact factor: 3.850

8.  Prognostic Significance of Cytoplasmic SPNS2 Expression in Patients with Oral Squamous Cell Carcinoma.

Authors:  Jeng-Wei Lu; Yen-Shuo Tseng; Yu-Sheng Lo; Yueh-Min Lin; Chung-Min Yeh; Shu-Hui Lin
Journal:  Medicina (Kaunas)       Date:  2021-02-12       Impact factor: 2.430

9.  Acid ceramidase induces sphingosine kinase 1/S1P receptor 2-mediated activation of oncogenic Akt signaling.

Authors:  T H Beckham; J C Cheng; P Lu; Y Shao; D Troyer; R Lance; S T Marrison; J S Norris; X Liu
Journal:  Oncogenesis       Date:  2013-06-03       Impact factor: 7.485

10.  Impact of breast cancer surgery on angiogenesis circulating biomarkers: a prospective longitudinal study.

Authors:  Georgios K Georgiou; Maria Igglezou; Ioannis Sainis; Katerina Vareli; Haralampos Batsis; Evangelos Briasoulis; Michalis Fatouros
Journal:  World J Surg Oncol       Date:  2013-08-27       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.